NCT00704678 - Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis | Biotech Hunter

Enrollment

203

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

June 30, 2010

Conditions

Chronic Kidney Disease

Interventions

DRUG

SBR759

1g tid

DRUG

Sevelamer HCl

1.6 g tid

DRUG

Sevelamer HCl

1.5 g tid

DRUG

Sevelamer HCl

0.8 g tid

Trial Locations (15)

Novartis Investigative Site, Kōriyama

Novartis Investigative Site, Midori

Novartis Investigative Site, Hitachiomiya

Novartis Investigative Site, Moriya

Novartis Investigative Site, Sashima-gun

Novartis Investigative Site, Takamatsu

Novartis Investigative Site, Tsu

Novartis Investigative Site, Nagano

Novartis Investigative Site, Okayama

Novartis Investigative Site, Sakai

Novartis Investigative Site, Kasukabe

Novartis Investigative Site, Shizuoka

Novartis Investigative Site, Changhua

Novartis Investigative Site, Kaoshiung

Novartis Investigative Site, Taipei